Featured
-
-
Article |
Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil
- Bingxue Yang
- , Xinran Xie
- & Shiyi Zhang
-
Article |
Possible mechanism for improving the endogenous immune system through the blockade of peripheral μ-opioid receptors by treatment with naldemedine
- Eizoh Gondoh
- , Yusuke Hamada
- & Minoru Narita
-
Article
| Open AccessSimultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma
- Richard A. Noble
- , Huw Thomas
- & Stephen R. Wedge
-
Article
| Open AccessTherapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic
- Ulrike Tontsch-Grunt
- , Paula-Elena Traexler
- & Flavio Solca
-
Article |
Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
- Ayako Nakayama
- , Takeyuki Nagashima
- & Masashi Shimazaki
-
Clinical Study
| Open AccessPhase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
- Monica M Mita
- , Alain C Mita
- & Geoffrey I Shapiro
-
Review
| Open AccessTargeting apoptosis in acute myeloid leukaemia
- Philippe A Cassier
- , Marie Castets
- & Norbert Vey
-
Translational Therapeutics
| Open AccessLurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
- Cristina Belgiovine
- , Ezia Bello
- & Maurizio D'Incalci
-
Translational Therapeutics
| Open AccessHuman equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
- Bruno Vincenzi
- , Silvia Stacchiotti
- & Giuseppe Tonini
-
Clinical Study
| Open AccessA phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
- Glen J Weiss
- , Jordan Waypa
- & Vivek Khemka
-
Translational Therapeutics
| Open AccessEfficacy of anti-PD-1 therapy in patients with melanoma brain metastases
- Sagun Parakh
- , John J Park
- & Matteo S Carlino
-
Mini Review
| Open AccessHallmarks of response to immune checkpoint blockade
- Alexandria P Cogdill
- , Miles C Andrews
- & Jennifer A Wargo
-
Epidemiology
| Open AccessStatin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study
- Ronan T Gray
- , Maurice B Loughrey
- & Helen G Coleman
-
Clinical Study
| Open AccessSecond-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group
- F Koinis
- , S Agelaki
- & A Kotsakis
-
Clinical Study
| Open AccessEfficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data
- Chikuma Hamada
- , Takuji Okusaka
- & Shota Okamura
-
Clinical Study
| Open AccessPhase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
- Rastislav Bahleda
- , Juneko E Grilley-Olson
- & Jean-Charles Soria
-
Clinical Study
| Open AccessThe oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
- Rachna T Shroff
- , Mark Yarchoan
- & Nilofer S Azad
-
Clinical Study
| Open AccessA phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
- M A Calegari
- , A Inno
- & C Barone
-
Translational Therapeutics
| Open AccessPretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
- Didier Meulendijks
- , Linda M Henricks
- & Jan H M Schellens
-
Translational Therapeutics
| Open AccessTowards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer
- A Janssen
- , C P M Verkleij
- & R ter Heine
-
Translational Therapeutics
| Open AccessCharacterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy
- Amir Faisal
- , Grace W Y Mak
- & Spiros Linardopoulos
-
Letter to the Editor
| Open AccessReply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
- Samantha Bowyer
- , Prashanth Prithviraj
- & Oliver Klein
-
Clinical Study
| Open AccessCombination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
- Roberto Pili
- , Glenn Liu
- & Michael A Carducci
-
Clinical Study
| Open AccessA phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
- Richard H Wilson
- , TR Jeffry Evans
- & Ruth Plummer
-
Translational Therapeutics
| Open AccessAurora B expression modulates paclitaxel response in non-small cell lung cancer
- Ahmed SK Al-Khafaji
- , Michael PA Davies
- & Triantafillos Liloglou
-
Clinical Study
| Open AccessEfficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
- Bum Jun Kim
- , Changhoon Yoo
- & Heung-Moon Chang
-
Short Communication
| Open AccessCombined oral contraceptive use before the first birth and epithelial ovarian cancer risk
- Linda S Cook
- , Claire R Pestak
- & Nhu Le
-
Letter to the Editor |
Comment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’
- Luca Mascitelli
- & Mark R Goldstein
-
Letter to the Editor |
Reply to Comment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’
- Ange Wang
- , Aaron K Aragaki
- & Marcia L Stefanick
-
Epidemiology
| Open AccessReproductive and menstrual factors and colorectal cancer incidence in the Women’s Health Initiative Observational Study
- Neil Murphy
- , Linzhi Xu
- & Marc J Gunter
-
Editorial
| Open AccessTrastuzumab cardiotoxiciy: the age-old balance of risk and benefit
- Michael S Ewer
- & Steven M Ewer
-
Clinical Study
| Open AccessCaphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation
- Nathaniel Treister
- , Michael Nieder
- & Lillian Sung
-
Translational Therapeutics
| Open AccessAn individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
- Lishuang Qi
- , Yang Li
- & Zheng Guo
-
Epidemiology
| Open AccessThe use of drugs acting on the renin–angiotensin system and the incidence of pancreatic cancer
- Victoria Mandilaras
- , Nathaniel Bouganim
- & Laurent Azoulay
-
Clinical Study
| Open AccessQuality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
- Jonathan A Ledermann
- , Philipp Harter
- & Ursula Matulonis
-
Clinical Study
| Open AccessPredictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours
- Faidon-Marios Laskaratos
- , Martin Walker
- & Christos Toumpanakis
-
Clinical Study
| Open AccessRandomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
- Angus G Dalgleish
- , Justin Stebbing
- & Satvinder S Mudan
-
Translational Therapeutics
| Open AccessComparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer
- Ana Luiza Ribeiro de Souza
- , Kayla Marra
- & Brian W Pogue
-
Translational Therapeutics
| Open AccessA functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
- Madelon Q Wentink
- , Henk J Broxterman
- & Henk M W Verheul
-
Epidemiology
| Open AccessStatin use and all-cancer survival: prospective results from the Women’s Health Initiative
- Ange Wang
- , Aaron K Aragaki
- & Marcia L Stefanick
-
-
Letter to the Editor
| Open AccessComment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort’
- Caterina Vivaldi
- , Lorenzo Fornaro
- & Enrico Vasile
-
Letter to the Editor
| Open AccessReply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort’
- Simon Pernot
- , Jean-Baptiste Bachet
- & Julien Taieb
-
Clinical Study
| Open AccessEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
- S Bowyer
- , P Prithviraj
- & O Klein
-
Clinical Study
| Open AccessMipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
- D Mahalingam
- , G Wilding
- & M Carducci
-
Epidemiology
| Open AccessThe effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients
- Jente van Staalduinen
- , Martine Frouws
- & Gerrit-Jan Liefers
-
Clinical Study
| Open AccessImmunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
- Angelica Loskog
- , Aglaia Maleka
- & Gustav Ullenhag
-
Translational Therapeutics
| Open AccessSoluble tumour necrosis factor receptor type II and survival in colorectal cancer
- Ana Babic
- , Sonali M Shah
- & Kimmie Ng
-
Editorial
| Open AccessPARP inhibitors: the race is on
- Jessica S Brown
- , Stan B Kaye
- & Timothy A Yap